|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/07/19 Anavex Life Sciences Corp. 10-Q 6/30/19 36:1.7M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 216K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 17K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 17K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
11: R1 Document and Entity Information HTML 53K
12: R2 Interim Condensed Consolidated Balance Sheets HTML 63K
(Unaudited)
13: R3 Interim Condensed Consolidated Balance Sheets HTML 28K
(Unaudited) (Parenthetical)
14: R4 Interim Condensed Consolidated Statements of HTML 60K
Operations (Unaudited)
15: R5 Interim Condensed Consolidated Statements of Cash HTML 54K
Flows (Unaudited)
16: R6 Interim Condensed Consolidated Statement of HTML 77K
Changes in Stockholders' Equity (Unaudited) (Usd
$)
17: R7 Business Description and Basis of Presentation HTML 32K
18: R8 Recent Accounting Pronouncements HTML 21K
19: R9 Other Income HTML 16K
20: R10 Equity Offering Agreements HTML 25K
21: R11 Commitments HTML 47K
22: R12 Subsequent Events HTML 16K
23: R13 Recent Accounting Pronouncements (Policies) HTML 20K
24: R14 Commitments (Tables) HTML 46K
25: R15 Business Description and Basis of Presentation HTML 16K
(Details Narrative)
26: R16 Other Income (Details Narrative) HTML 16K
27: R17 Equity Offering Agreements (Details Narrative) HTML 52K
28: R18 Commitments (Details) HTML 37K
29: R19 Commitments (Details 1) HTML 55K
30: R20 Commitments (Details 2) HTML 19K
31: R21 Commitments (Details 3) HTML 24K
32: R22 Commitments (Details Narrative) HTML 31K
33: R23 Subsequent Events (Details Narrative) HTML 16K
35: XML IDEA XML File -- Filing Summary XML 57K
34: EXCEL IDEA Workbook of Financial Reports XLSX 33K
5: EX-101.INS XBRL Instance -- avxl-20190630 XML 449K
7: EX-101.CAL XBRL Calculations -- avxl-20190630_cal XML 71K
8: EX-101.DEF XBRL Definitions -- avxl-20190630_def XML 180K
9: EX-101.LAB XBRL Labels -- avxl-20190630_lab XML 463K
10: EX-101.PRE XBRL Presentations -- avxl-20190630_pre XML 300K
6: EX-101.SCH XBRL Schema -- avxl-20190630 XSD 76K
36: ZIP XBRL Zipped Folder -- 0001213900-19-014791-xbrl Zip 52K
Exhibit 31.1
CERTIFICATION
I, Christopher Missling, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2019 of Anavex Life Sciences Corp. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 7, 2019
| /s/ Christopher Missling, PhD | |
| Christopher Missling, PhD | |
| Chief Executive Officer, President and Secretary | |
| (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/7/19 | None on these Dates | ||
| For Period end: | 6/30/19 | |||
| List all Filings | ||||